As a Free StocksGuide user, you can view scores for all 7,048 stocks worldwide.
7 Analysts have issued a LAVA Therapeutics NV forecast:
7 Analysts have issued a LAVA Therapeutics NV forecast:
| Mar '25 |
+/-
%
|
||
| Revenue | 12 12 |
4%
4%
|
|
| Gross Profit | - - |
-
|
|
| EBITDA | -58 -58 |
91%
91%
|
|
| EBIT (Operating Income) EBIT | -58 -58 |
83%
83%
|
|
| Net Profit | -49 -49 |
72%
72%
|
|
In millions USD.
If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.
LAVA Therapeutics NV operates as a biotechnology company, which develops immune oncology biopharmaceutical products. The firm develops next generation T-cell engaging bispecific antibodies to treat cancer. The company was founded by Erik van den Berg in 2016 and is headquartered in Utrecht, the Netherlands.
| Head office | Netherlands |
| CEO | Stephen Hurly |
| Employees | 34 |
| Founded | 2016 |
| Website | www.lavatherapeutics.com |
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.


